Avinger to Announce Full Year 2023 Results on March 20, 2024
Avinger to Announce Full Year 2023 Results on March 20, 2024
REDWOOD CITY, CA / ACCESSWIRE / March 12, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the fourth quarter and full year 2023 after the close of trading on Wednesday, March 20, 2024. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
加利福尼亚州雷德伍德城/ACCESSWIRE/2024年3月12日/Avinger, Inc.（纳斯达克股票代码：AVGR）是一家处于商业阶段的医疗器械公司，销售第一款也是唯一一款用于血管内影像引导、基于导管的血管疾病诊断和治疗系统，今天宣布，将在2024年3月20日星期三收盘后发布其第四季度和2023年全年的财务业绩。公司将在太平洋时间下午 1:30 /美国东部时间下午 4:30 开始举行电话会议。
To join the call by telephone, please dial +1-973-528-0011 and use passcode 669593. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at .
要通过电话加入通话，请拨打 +1-973-528-0011 并使用密码 669593。电话会议的网络直播将在公司网站的投资者关系页面上在线播出，网址为。
A replay of the webcast will be made available on Avinger's website, , shortly after completion of the call.
电话会议结束后不久，将在Avinger的网站上重播网络直播。
About Avinger, Inc.
关于 Avinger, Inc.
Avinger is a commercial-stage medical device company that designs and develops the first and only image-guided, catheter-based system for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD). PAD is estimated to affect over 12 million people in the U.S. and over 200 million worldwide. Avinger is dedicated to radically changing the way vascular disease is treated through its Lumivascular platform, which currently consists of the Lightbox imaging console, the Ocelot and Tigereye family of chronic total occlusion (CTO) catheters, and the Pantheris family of atherectomy devices. Avinger is based in Redwood City, California. For more information, please visit .
Avinger是一家处于商业阶段的医疗器械公司，设计和开发了第一个也是唯一一个用于诊断和治疗外周动脉疾病（PAD）患者的基于图像引导的导管系统。据估计，PAD将影响美国超过1200万人，全球超过2亿人。Avinger致力于通过其Lumibasular平台从根本上改变血管疾病的治疗方式，该平台目前包括Lightbox成像控制台、Ocelot和Tigereye系列慢性全闭塞（CTO）导管以及Pantheris系列动脉切除术设备。Avinger 总部位于加利福尼亚州雷德伍德城。欲了解更多信息，请访问。
Follow Avinger on Twitter and Facebook.
在推特和脸书上关注 Avinger。
Investor Contact:
投资者联系人：
Matt Kreps
Darrow Associates Investor Relations
(214) 597-8200
mkreps@darrowir.com
马特·克雷普斯
达罗联合投资者关系
(214) 597-8200
mkreps@darrowir.com
SOURCE: Avinger, Inc.
来源：Avinger, Inc.
译文内容由第三方软件翻译。